Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob disease

Proteomics

Volumn 10, Issue 1, 2010, Pages 81-89

  Steinacker, Petra ^a   Rist, Wolfgang ^b   Swiatek de Lange, Magdalena ^b   Lehnert, Stefan ^a   Jesse, Sarah ^a   Pabst, Alice ^a   Tumani, Hayrettin ^a   Von Arnim, Christine A F ^a   Mitrova, Eva ^c   Kretzschmar, Hans A ^d   Lenter, Martin ^b   Wiltfang, Jens ^e   Otto, Markus ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Boehringer Ingelheim GmbH and Co KG   (Germany)

^c INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Biomarker identification; Biomedicine; Creutzfeldt jakob disease; Differential diagnosis; SELDI TOF MS; Ubiquitin

Indexed keywords

BIOLOGICAL MARKER; PROTEIN 14 3 3; TAU PROTEIN; UBIQUITIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION; PROTEOMICS; SCREENING TEST; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION STUDY; WESTERN BLOTTING;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; CREUTZFELDT-JAKOB SYNDROME; FEMALE; HUMANS; MALE; TANDEM MASS SPECTROMETRY; UBIQUITIN;

EID: 73549105915     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200900246     Document Type: Article

References (37)

1. Steinhoff, B. J., Racker, S., Herrendorf, G., Poser, S. et al., Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch. Neurol. 1996, 53, 162-166.
2. Kretzschmar, H. A., Ironside, J. W., DeArmond, S. J., Tateishi, J., Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch. Neurol. 1996, 53, 913-920.
3. Hsich, G., Kenney, K., Gibbs, C. J., Lee, K. H., Harrington, M. G., The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N. Engl. J. Med. 1996, 335, 924-930.
4. Kenney, K., Brechtel, C., Takahashi, H., Kurohara, K. et al., An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Ann. Neurol. 2000, 48, 395-398.
5. Geschwind, M. D., Martindale, J., Miller, D., DeArmond, S. J. et al., Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch. Neurol. 2003, 60, 813-816.
6. Green, A. J., Knight, R. S., Macleod, M. A., Lowman, A.,Will, R. G., Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology 2001, 56, 986-987.
7. Otto, M., Esselmann, H., Schulz-Shaeffer, W., Neumann, M. et al., Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 2000, 54, 1099-1102.
8. Brechlin, P., Jahn, O., Steinacker, P., Cepek, L. et al., Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics 2008, 8, 4357-4366.
9. Carrette, O., Burkhard, P. R., Hughes, S., Hochstrasser, D. F., Sanchez, J. C., Truncated cystatin C in cerebrospiral fluid: Technical [corrected] artefact or biological process? Proteomics 2005, 5, 3060-3065.
10. Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O. et al., A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003, 3, 1486-1494.
11. Lewczuk, P., Esselmann, H., Groemer, T. W., Bibl, M. et al., Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-offlight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol. Psychiatry 2004, 55, 524-530.
12. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J. et al., Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359, 572-577.
13. Sanchez, J. C., Guillaume, E., Lescuyer, P., Allard, L. et al., Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2004, 4, 2229-2233.
14. Simonsen, A. H.,McGuire, J., Hansson, O., Zetterberg, H. et al., Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch. Neurol. 2007, 64, 366-370.
15. Simonsen, A. H., McGuire, J., Podust, V. N., Davies, H. et al., Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol. Aging 2008, 29, 961-968.
16. Will, R. G., Epidemiology of Creutzfeldt-Jakob disease. Br. Med. Bull. 1993, 49, 960-970.
17. Otto, M., Wiltfang, J., Cepek, L., Neumann, M. et al., Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002, 58, 192-197.
18. McKhann, G., Drachman, D., Folstein, M., Katzman, R. et al., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34, 939-944.
19. McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K. et al., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996, 47, 1113-1124.
20. Youden, W. J., Index for rating diagnostic tests. Cancer 1950, 3, 32-35.
21. Metz, C. E., Basic principles of ROC analysis. Semin. Nucl. Med. 1978, 8, 283-298.
22. Shevchenko, A., Wilm, M., Vorm, O., Mann, M., Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996, 68, 850-858.
23. Biemann, K., Sequencing of peptides by tandem mass spectrometry and high-energy collision-induced dissociation. Methods Enzymol. 1990, 193, 455-479.
24. Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C. et al., Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999, 52, 1555-1562.
25. Piubelli, C., Fiorini, M., Zanusso, G., Milli, A. et al., Searching for markers of Creutzfeldt-Jakob disease in cerebrospinal fluid by two-dimensional mapping. Proteomics 2006, 6, S256-S261.
26. Manaka, H., Kato, T., Kurita, K., Katagiri, T. et al., Marked increase in cerebrospinal fluid ubiquitin in Creutzfeldt-Jakob disease. Neurosci. Lett. 1992, 139, 47-49.
27. Abdi, F., Quinn, J. F., Jankovic, J., McIntosh, M. et al., Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 2006, 9, 293-348.
28. Wang, G. P., Khatoon, S., Iqbal, K., Grundke-Iqbal, I., Brain ubiquitin is markedly elevated in Alzheimer disease. Brain Res. 1991, 566, 146-151.
29. Davidsson, P., Westman-Brinkmalm, A., Nilsson, C. L., Lindbjer, M. et al., Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 2002, 13, 611-615.
30. Iqbal, K., Grundke-Iqbal, I., Elevated levels of tau and ubiquitin in brain and cerebrospinal fluid in Alzheimer's disease. Int. Psychogeriatr. 1997, 9, 289-296. Discussion 317-221.
31. Blennow, K., Davidsson, P., Wallin, A., Gottfries, C. G., Svennerholm, L., Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia. Int. Psychogeriatr. 1994, 6, 13-22. Discussion 59-60.
32. Majetschak, M., King, D. R., Krehmeier, U., Busby, L. T. et al., Ubiquitin immunoreactivity in cerebrospinal fluid after traumatic brain injury: clinical and experimental findings. Crit. Care Med. 2005, 33, 1589-1594.
33. Kudo, T., Iqbal, K., Ravid, R., Swaab, D. F., Grundke-Iqbal, I., Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels. Brain Res. 1994, 639, 1-7.
34. Skoog, I., Vanmechelen, E., Andreasson, L. A., Palmertz, B. et al., A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration 1995, 4, 433-442.
35. Verpillot, R., Otto, M., Klafki, H., Taverna, M., Simultaneous analysis by capillary electrophoresis of five amyloid peptides as potential biomarkers of Alzheimer's disease. J. Chromatogr. A 2008, 1214, 157-164.
36. Emanuele,V. A., 2nd, Gurbaxani, B. M., Benchmarking currently available SELDI-TOF MS preprocessing techniques. Proteomics 2009, 9, 1754-1762.
37. Riester, D., Wirsching, F., Salinas, G., Keller, M. et al., Thrombin inhibitors identified by computer-assisted multiparameter design. Proc. Natl. Acad. Sci. USA 2005, 102, 8597-8602.